GlassScriptPhysician profile
Petre Udrea
NPI 1245232024
$3,556.89
in general payments reported to CMS, 2019-2025
39 companies · $44.49 in 2025
The $44.49 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $588 · 2020: $507 · 2021: $1,010 · 2022: $997 · 2023: $255 · 2024: $155 · 2025: $44.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $454.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $571.20 | 2019-2025 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $473.46 | 2019-2022 | |
| Biogen, INC. | $427.97 | 2019-2022 | |
| Amgen INC. | $279.55 | 2019-2021 | |
| Abbvie INC. | $221.34 | 2021-2023 | Botox |
| Supernus Pharmaceuticals, INC. | $110.79 | 2019-2022 | |
| Ucb, INC. | $104.22 | 2019-2022 | |
| Pfizer INC. | $99.44 | 2022-2023 | |
| Allergan, INC. | $99.41 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $93.78 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $83.86 | 2020-2023 | Nuplazid |
| Genzyme Corporation | $82.25 | 2019-2022 | |
| Horizon Therapeutics Plc | $69.37 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $68.27 | 2022 | |
| Acorda Therapeutics, INC | $65.41 | 2020-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Petre Udrea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.